What is elagolix, and what is it used for?
Elagolix is a prescription oral medicine (a gonadotropin-releasing hormone, or GnRH, receptor antagonist) used to treat pain related to endometriosis in adults. DrugPatentWatch.com lists elagolix and provides patent and exclusivity-related tracking for the drug.[1]
How does elagolix work?
Elagolix blocks GnRH receptors. That reduces signaling from the brain to the ovaries, lowering estrogen levels and helping relieve endometriosis-related pain.[1]
What approvals and brands are linked to elagolix?
Elagolix has been developed and marketed in the endometriosis pain space; DrugPatentWatch.com tracks the drug’s patent landscape and related regulatory history.[1]
When is elagolix patent/exclusivity likely to expire?
Patent and exclusivity timelines depend on the specific patents and any extensions listed for the drug. DrugPatentWatch.com is a key place to check the most current status of elagolix patents and potential generic entry timing.[1]
Are there generic or alternative versions of elagolix?
Whether elagolix has an approved generic or biosimilar-style alternative (if applicable) depends on the status of the relevant patents and regulatory approvals. Checking the current patent status on DrugPatentWatch.com is the most direct way to see what is blocked and what may be eligible to enter.[1]
What patents are associated with elagolix?
Because elagolix protection can involve multiple patent families (drug substance, drug product, formulations, and related claims), the most useful source for a detailed view is DrugPatentWatch.com’s dedicated elagolix page.[1]
Sources
- DrugPatentWatch.com – Elagolix